Login
Corrs’ coffers healthy after acting on major merger
Corrs Chambers Westgarth and Chapman Tripp have acted on one of the largest health sector transactions in recent years.
Digital
Firms: Corrs Chambers Westgarth (Zuellig – the owners of Symbion); Chapman Tripp (EBOS Group)
To continue reading the rest of this article, please log in.
Create free account to get unlimited news articles and more!
Deal: Australian pharmaceutical wholesaler Symbion has merged with New Zealand’s EBOS Group
Area: M&A
Value: $NZ1.5 billion
Key players: For Corrs, the deal was lead by corporate and M&A partner Justin Fox (pictured). Alister McDonald led the transaction for Chapman Tripp
Deal significance: This is one of the largest health sector transactions in recent years. The merger has created Australasia’s largest wholesaler and distributor of healthcare products and will see EBOS become the third largest New Zealand listed company by revenue. Corrs’ lead partner Justin Fox said: “Corrs is proud to have been involved in this deal, which is important to every Australian household.”
